EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HCAR score as a prognostic biomarker of survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy

Erkan Topkan, Efsun Somay, Duriye Ozturk, Ugur Selek

Biomolecules and Biomedicine · 2025

DOI: 10.17305/bb.2025.13398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2025. Verfasst von Erkan Topkan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Türkiye. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Chemoradiotherapy, Nasopharyngeal Neoplasms, C-Reactive Protein. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nasopharyngeal carcinoma (NPC) is an aggressive malignancy of the head and neck that is often diagnosed at a locally advanced stage (LANPC). In such cases, intensity-modulated radiotherapy combined with concurrent chemoradiotherapy (CCRT) is the standard treatment; however, the occurrence of distant metastasis and treatment failure remains prevalent. This study evaluates the prognostic significance of a novel composite score that combines hemoglobin levels and the C-reactive protein-to-albumin ratio (HCAR) in LANPC patients undergoing CCRT. We conducted a retrospective analysis of 233 LANPC patients treated with intensity-modulated radiotherapy and platinum-based CCRT from 2011 to 2020. Receiver operating characteristic curve analysis determined pretreatment hemoglobin (Hb) and C-reactive protein-to-albumin ratio (CAR) cut-offs of 11.0 g/dL and 3.0, respectively, which were utilized to create a three-tiered HCAR score: HCAR-0 (Hb ≥11.0 g/dL and CAR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaChemoradiotherapyNasopharyngeal NeoplasmsC-Reactive ProteinBiomarkers, TumorHumansMaleFemaleMiddle AgedAdultPrognosisRetrospective StudiesAgedHemoglobinsRadiotherapy, Intensity-Modulated

Substanzen

C-Reactive ProteinBiomarkers, TumorHemoglobins

Autor:innen und Institutionen

  • Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Türkiye.
  • Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Türkiye.
  • Department of Radiation Oncology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Türkiye.
  • Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Türkiye.

Zitieren

APA

Topkan, E., Somay, E., Ozturk, D., & Selek, U. (2025). HCAR score as a prognostic biomarker of survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2025.13398

Vancouver

Topkan E, Somay E, Ozturk D, Selek U. HCAR score as a prognostic biomarker of survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Biomolecules and Biomedicine. 2025. doi:10.17305/bb.2025.13398

BibTeX
@article{Topkan2025,
  author = {Topkan, Erkan and Somay, Efsun and Ozturk, Duriye and Selek, Ugur},
  title = {HCAR score as a prognostic biomarker of survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy},
  journal = {Biomolecules and Biomedicine},
  year = {2025},
  doi = {10.17305/bb.2025.13398}
}
Kostenlos starten →